Although no published data are currently available in indexed literature on the role of VEGF and VEGFR-2 SNPs in predicting the response and outcome related to BV treatment in colorectal cancer, a recent retrospective experience has shown a significant correlation of VEGF −1498 TT variant of VEGF −1498 C/T SNP with worse PFS in a population of mCRC patients treated with FOLFIRI plus BV as first-line regimen (Loupakis et al, 2009). This evidence concerns the gene VEGFA and colorectal cancer.